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ing inhaled corticosteroids. Within 3 months of starting
zafirlukast, outpatient visits, inpatient stays, emergency de-
partment visits, and albuterol prescriptions were all signifi-
cantly reduced compared with the previous 3 months (p 
0.002). In the 3 months before starting zafirlukast, 55%
of patients received oral corticosteroids, compared with
15% in the 3 months after commencing zafirlukast.
CONCLUSIONS: Retrospective data analysis may be
valuable in determining how therapies are used in clinical
practice and in measuring the effectiveness of asthma ther-
apies outside of controlled clinical trials. This study shows
that the addition of zafirlukast to existing asthma regi-
mens was associated with reduced healthcare utilisation
and reduced need for oral corticosteroids and albuterol,
which may translate into reduced direct healthcare costs.
PTH10
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OBJECTIVES: Costs for medication are beside productiv-
ity loss most relevant for patients with chronic lung disease
like asthma and COLD. In Germany hospital prices for
pharmaceuticals are not fixed by the government and not
accessible through administrative data. Official sales-prices
(Rote Liste) do not represent opportunity costs.
METHODS: To improve the evaluation of medication
costs we calculated the resources used by measuring the
units of 100 fully hospitalized patients of a rehabilitation
clinic for chronic lung diseases and validated with unit
prices from Rote Liste. These costs were compared with
average expenses for medication per day according to the
clinic’s routine calculation. To assess medication costs in
an outpatient setting we used a cost diary, where patients
note all health care resource uses, and a standardized ret-
rospective questionnaire.
RESULTS: Medication costs in inpatient rehabilitation
setting were 11,4 DM per day (SD 5,0) validated by Rote
Liste. Actual average expenses for the clinic were 2,8 DM
(Rate: 1:4). Medication costs in outpatient setting were
260 DM per month according to the cost diary (n  28)
and 270 DM using the questionnaire (n  41). Dropouts
were remarkably higher using the diary (44%), compared
to the questionnaire (18%).
CONCLUSIONS: Investigators should be aware of the
fact, that the difference between medication costs vali-
dated by sales prices and hospital expenses can be crucial
for the result of an economic evaluation especially for
chronic diseases with mainly pharmaceutical therapy. In
an acute hospital setting this difference might even be
higher, further research is necessary. To assess medication
costs in an outpatient setting a retrospective questionnaire
seems to be the most reliable and practicable way.
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OBJECTIVES: We currently have over 2,000 active pre-
scriptions for albuterol inhalers. Improper use could render
medication not effective and result in over prescribing. At
an average wholesale price of $25.00 per inhaler the cost is
not insignificant. We wanted to know if patients with air-
way obstruction were able to deliver medication through
their inhaler correctly and whether monitoring would be
cost effective in terms of training and education cost.
METHODS: We sampled thirty-eight consecutive patients
in pulmonary clinic with chronic obstructive pulmonary dis-
ease being treated with albuterol metered does inhalers.
Assessment was performed using an aerosol inhalation
monitor and observation. Critical steps evaluated in the
maneuver: 1. Shaking canister, 2. Begin inspiration between
functional residual capacity and residual volume, 3. Firing
of inhaler and synchrony with inspiration, and 4. Breath
hold time. Inhaler performance, costs of medication, and
training costs were evaluated using Decisional Analysis soft-
ware (Data 3.5).
RESULTS: Only thirty three percent of patients could per-
form the inhaler technique correctly on screening. Sixty
seven percent failed and underwent training; of this group
which failed ninety seven percent passed after training.
CONCLUSIONS: We found this process of inhaler mon-
itoring to be cost effective for our patient population.
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OBJECTIVES: The objective of this study was to collect
information about health care resources used in the In-
tensive Care Unit (ICU) to treat pediatric patients with
acute respiratory distress syndrome, and to calculate to-
tal treatment costs. To collect this information, the use of
administrative databases or hospital records was consid-
ered. The latter method was used. Costs for each re-
source were estimated through micro and gross costing.
METHODS: A non-comparative retrospective cohort study
was conducted using hospital records. The study popula-
tion was comprised of pediatric patients treated in the
ICU of the Sainte-Justine Hospital. Selected were ninety-
six (96) patients who required ventilation support fol-
lowing acute respiratory distress syndrome in 1996. All
hospital files were reviewed to collect data on patient
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characteristics, diagnoses, hospitalizations, professional
fees, medical interventions, medication use, laboratory
tests, and complications. These data were collected from
the first day the patients were admitted in the ICU, until the
day they were transferred to another ward. A trauma phy-
sician, a pharmacist, and an inhalation therapist helped to
develop the Clinical Research Form (CRF). Two research
nurses completed the CRFs, and a clinical research assis-
tant collected cost data.
RESULTS: The use of micro costing is a very reliable way
of estimating treatment costs. However, it was found to
be a long and expensive process. In our study, research
nurses spent up to 8 hours per record to collect the infor-
mation needed to complete the CRF.
CONCLUSION: Given the extensive time needed to realize
micro costing studies, it is understandable that modeliza-
tion has occupied a big place in pharmacoeconomic evalua-
tions. However, in some cases, even modelization cannot
replace micro costing. Alternative ways, such as the use of
administrative databases, should be considered. However,
in Quebec, there is still a need to assess the reliability of us-
ing administrative databases for economic evaluations.
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OBJECTIVES: The objective of portfolio management is
to create the most value from a portfolio of projects. It
attempts to ensure that the projects in the portfolio meet
the strategic goals of the business by determining which
projects are to be funded and at what levels. This study
investigates the application of two portfolio management
techniques involving Monte-Carlo simulation and the
Pearson Index to two diverse situations: pharmaceutical
R&D investment prioritisation decisions and health eco-
nomic evaluations using cost-effectiveness analysis.
METHODS: To assist the decision-maker to prioritise
pharmaceutical R&D projects in which to invest, we con-
structed a model involving Monte-Carlo simulation and
the Pearson Index. This model was applied to data on cost
of development and probability of success for each clinical
development phase (I–III), as well as overall return-on-
investment (ROI) for each project in the drug portfolio. To
assist healthcare policy-makers to select the cost-effective
treatment strategy, we constructed a model using Monte-
Carlo simulation, to incorporate variability in medical re-
source use and unit costs, and the bootstrap method to es-
timate the 95% confidence interval for the incremental
cost-effectiveness ratio (ICER). This model was applied to
data from a multinational health economic trial.
RESULTS: For pharmaceutical R&D investment prioriti-
sation decisions, we derived a probability distribution for
the Pearson Index for each project which was then used to
prioritise project selection in light of uncertainty in devel-
opment costs, success probabilities and overall ROI. In ad-
dition, we derived an estimate of the ICER and its 95%
confidence interval, which was then used to select the cost-
effective treatment strategy.
CONCLUSIONS: Portfolio management techniques can
successfully be used to support the decision-maker in mak-
ing optimal decisions in pharmaceutical R&D project se-
lection and to select the cost-effective treatment strategy in
light of the uncertainty/variability in input parameters.
